Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 13, 2019 - Issue
Submit an article Journal homepage
112
Views
14
CrossRef citations to date
0
Altmetric
Review

A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer

Ricardo Costa1 Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, [email protected]Correspondence[email protected]
,
Saif Zaman2 Morsani College of Medicine, University of South Florida, Tampa, FL, USA
,
Susan Sharpe3 Moffitt Biomedical Library, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
,
Irene Helenowski4 Department of Preventive Medicine, Northwestern University, Chicago, IL, USA
,
Colleen Shaw1 Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, [email protected]
,
Hyo Han1 Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, [email protected]
,
Hatem Soliman1 Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, [email protected]
&
Brian Czerniecki1 Department of Breast Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, [email protected]
 show all
Pages 309-316 | Published online: 14 Jan 2019

References

  • HammondMEHayesDFDowsettMAmerican Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancerJ Clin Oncol201028162784279520404251
  • WolffACHammondMEHicksDGRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateJ Clin Oncol201331313997401324101045
  • SlamonDJLeyland-JonesBShakSUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N Engl J Med20013441178379211248153
  • SwainSMBaselgaJKimSBPertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancerN Engl J Med2015372872473425693012
  • de AzambujaEHolmesAPPiccart-GebhartMLapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseLancet Oncol201415101137114625130998
  • Cancer Genome Atlas NetworkComprehensive molecular portraits of human breast tumoursNature20124907418617023000897
  • BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med2015373171627163926412456
  • ReckMRodríguez-AbreuDRobinsonAGPembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancerN Engl J Med2016375191823183327718847
  • AndréFO’ReganROzgurogluMEverolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trialLancet Oncol201415658059124742739
  • LoiSGiobbe-HurderABachelotTPhase 1b/2 study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: results from the PANACEA (IBCSG 4513/BIG 413/KEYNOTE-014) studySan Antonio Breast Cancer SymposiumDecember 5–9; 2017San Antonio, TX
  • VermaSMilesDGianniLTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
  • CostaRLBSolimanHCzernieckiBJThe clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectivesCancer Treat Rev20176110711529125981
  • GeYXiHJuSZhangXBlockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID miceCancer Lett2013336225325923523609
  • CuriglianoGRomieuGCamponeMA phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancerBreast Cancer Res Treat2016156230131026975189
  • CostaRBKurraGGreenbergLGeyerCEEfficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancerAnn Oncol201021112153216020351072
  • DisisMLWallaceDRGooleyTAConcurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancerJ Clin Oncol200927284685469219720923

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.